# the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

> **NCT04430361** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Tumor
- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Megestrol
- **DRUG:** 5-HT3 receptor antagonist
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT04430361
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-07
- **Primary completion:** 2020-12-30
- **Final completion:** 2021-05-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04430361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04430361, "the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04430361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*